EHDNEuropean Huntington's Disease Network
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Active Biotech AB (STO:ACTI), a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer, announced on Thursday that initial data from the phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented by global coordinating principal investigator, Dr Ralf Railmann, at the scientific conference 'European Huntington's Disease Network (EHDN) plenary meeting 2018' to be held from 14 September 2018 to 16 September 2018 in Vienna.
Aziz NA, Jurgens CK, Landwehrmeyer GB, EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, et al.
According to the chairman of the European Huntington's Disease Network (EHDN), GB Landwehrmeyer, this meta-analysis indicates that Huntexil has the potential to be an important therapeutic advance in Huntington's disease patients.